ガランタミン (Japanese Wikipedia)

Heinrich, M.; Teoh, H.L. (2004). “Galanthamine from snowdrop – the development of a modern drug against Alzheimer's disease from local Caucasian knowledge”. Journal of Ethnopharmacology 92 (2–3): 147–162. doi:10.1016/j.jep.2004.02.012. PMID 15137996.
Birks, J; Birks, Jacqueline (2006). Birks, Jacqueline. ed. “Cholinesterase inhibitors for Alzheimer's disease”. Cochrane database of systematic reviews (Online) (1): CD005593. doi:10.1002/14651858.CD005593. PMID 16437532.
Greenblatt, HM; Kryger, G; Lewis, T; Silman, I; Sussman, JL (1999). “Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3Å resolution”. FEBS Lett 463 (3): 321–26. doi:10.1016/S0014-5793(99)01637-3. PMID 10606746.
Woodruff-Pak, DS; Vogel Rw, 3rd; Wenk, GL (2001). “Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning”. Proceedings of the National Academy of Sciences of the United States of America 98 (4): 2089–94. doi:10.1073/pnas.031584398. PMC 29386. PMID 11172080.

fda.gov

“FDA ALERT: Galantamine hydrobromide (marketed as Razadyne, formerly Reminyl) - Healthcare Professional Sheet”. Postmarket Drug Safety Information for Patients and Providers. Food and Drug Administration (May 2005). 2010年4月2日閲覧。
“Safety Alerts for Human Medical Products > Reminyl (galantamine hydrobromide)”. # MedWatch The FDA Safety Information and Adverse Event Reporting Program. Food and Drug Administration (March 2005). 2010年8月4日閲覧。
“Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)”. MedWatch, The FDA Safety Information and Adverse Event Reporting Program. Food and Drug Administration (April 2006). 2007年10月9日時点のオリジナルよりアーカイブ。2009年7月30日閲覧。

“Substances that enhance recall and lucidity during dreaming”. Stephen LaBerge - US Patent. 2007年10月29日閲覧。

Heinrich, M.; Teoh, H.L. (2004). “Galanthamine from snowdrop – the development of a modern drug against Alzheimer's disease from local Caucasian knowledge”. Journal of Ethnopharmacology 92 (2–3): 147–162. doi:10.1016/j.jep.2004.02.012. PMID 15137996.
Scott, LJ; Goa, KL (2000). “Galantamine: a review of its use in Alzheimer's disease”. Drugs 60 (5): 1095–122. PMID 11129124.
Birks, J; Birks, Jacqueline (2006). Birks, Jacqueline. ed. “Cholinesterase inhibitors for Alzheimer's disease”. Cochrane database of systematic reviews (Online) (1): CD005593. doi:10.1002/14651858.CD005593. PMID 16437532.
Greenblatt, HM; Kryger, G; Lewis, T; Silman, I; Sussman, JL (1999). “Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3Å resolution”. FEBS Lett 463 (3): 321–26. doi:10.1016/S0014-5793(99)01637-3. PMID 10606746.
Woodruff-Pak, DS; Vogel Rw, 3rd; Wenk, GL (2001). “Galantamine: Effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning”. Proceedings of the National Academy of Sciences of the United States of America 98 (4): 2089–94. doi:10.1073/pnas.031584398. PMC 29386. PMID 11172080.